It ’s Medtronic vs. Abbott in Battle to Disrupt Diabetes Care

Don’t tell anyone, but it sure does look like Medtronic and Abbott Laboratories have been in a series of one-upping each other in the diabetes space recently. Dublin-based Medtronic fired the latest volley in the space by revealing it received FDA approval for a new arm indication for the Guardian Sensor 3. The continuous glucose monitoring sensor controls automated insulin delivery via Medtronic’s hybrid closed-loop system, the MiniMed 670G system. Network with your colleagues in medtech at ADM Cleveland, March 7–8, 2018. "The performance of the Guardian Sensor 3 has been extremely impressive, and this new arm indication now offers added convenience and flexibility for my patients who like to have as many options as possible to address their personal needs," said Bruce Bode, a specialist with Atlanta Diabetes Associates and a clinical associate professor at Emory University, in a release. "These continued enhancements demonstrate a keen focus on the part of Medtronic to deliver a positive patient experience in addition to optimizing outcomes through technological advancements—that can prove to be just as meaningful for quality of life." The system features the company's SmartGuard algorithm, which helps to increase time in range by automatically adjusting basal insulin delivery every five minutes based on real-time data delivered by the Guardian Sensor 3. The sensor incorporates diagnostic technology that continuously monitors sensor health to ensure the consistent ...
Source: MDDI - Category: Medical Devices Authors: Tags: Medical Device Business Source Type: news